1. Home
  2. ORMP vs IMAB Comparison

ORMP vs IMAB Comparison

Compare ORMP & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORMP
  • IMAB
  • Stock Information
  • Founded
  • ORMP 2002
  • IMAB 2014
  • Country
  • ORMP United States
  • IMAB United States
  • Employees
  • ORMP N/A
  • IMAB N/A
  • Industry
  • ORMP Biotechnology: Pharmaceutical Preparations
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORMP Health Care
  • IMAB Health Care
  • Exchange
  • ORMP Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • ORMP 90.7M
  • IMAB 79.9M
  • IPO Year
  • ORMP N/A
  • IMAB 2020
  • Fundamental
  • Price
  • ORMP $2.45
  • IMAB $0.95
  • Analyst Decision
  • ORMP Hold
  • IMAB Strong Buy
  • Analyst Count
  • ORMP 1
  • IMAB 3
  • Target Price
  • ORMP N/A
  • IMAB $8.00
  • AVG Volume (30 Days)
  • ORMP 478.1K
  • IMAB 289.3K
  • Earning Date
  • ORMP 03-05-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • ORMP N/A
  • IMAB N/A
  • EPS Growth
  • ORMP N/A
  • IMAB N/A
  • EPS
  • ORMP 0.11
  • IMAB N/A
  • Revenue
  • ORMP N/A
  • IMAB $3,313,984.00
  • Revenue This Year
  • ORMP N/A
  • IMAB N/A
  • Revenue Next Year
  • ORMP N/A
  • IMAB N/A
  • P/E Ratio
  • ORMP $22.15
  • IMAB N/A
  • Revenue Growth
  • ORMP N/A
  • IMAB N/A
  • 52 Week Low
  • ORMP $2.00
  • IMAB $0.84
  • 52 Week High
  • ORMP $3.67
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • ORMP 58.75
  • IMAB 43.17
  • Support Level
  • ORMP $2.16
  • IMAB $0.95
  • Resistance Level
  • ORMP $3.09
  • IMAB $1.04
  • Average True Range (ATR)
  • ORMP 0.15
  • IMAB 0.06
  • MACD
  • ORMP 0.03
  • IMAB -0.01
  • Stochastic Oscillator
  • ORMP 34.02
  • IMAB 10.53

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: